-
-
-
-
-
-
-
After-Hours Stock Movers: AVAV, PRAX, VSH, CNXC, SHAZ
-
-
-
-
-
-
-
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results
-
-
-
-
-
-
-
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
-
15,739 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

